Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05228275 · ClinicalTrials.gov registry record

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Children's Oncology Group.

Active
Registry status
549
Enrollment target
20
Study locations

NCT05228275 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 549 participants, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05228275, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is active but no longer recruiting, sponsored by Children's Oncology Group.

ACTIVE NOT RECRUITING
Registry status
549 participants
Enrollment target
20
Study locations

Study Summary

This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the body's immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the body's natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and number of vaccine doses or "boosts" (extra vaccine shots) may strengthen or diminish the body's protective immune response. This study may help researchers learn more about how the body's immune system responds to the COVID-19 vaccine when the vaccination is given during or after cancer treatment.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Survey Administration

Study Locations (20)

Florida

  • Golisano Children's Hospital of Southwest Florida - Fort Myers
  • UF Health Cancer Institute - Gainesville - Gainesville
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital - Hollywood
  • Nemours Children's Clinic-Jacksonville - Jacksonville
  • Nicklaus Children's Hospital - Miami
  • Nemours Children's Hospital - Orlando
  • Sacred Heart Hospital - Pensacola
  • Johns Hopkins All Children's Hospital - St. Petersburg
  • Tampa General Hospital - Tampa
  • Saint Joseph's Hospital/Children's Hospital-Tampa - Tampa

California

  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Rady Children's Hospital - San Diego - San Diego

Illinois

  • University of Illinois - Chicago
  • Saint Jude Midwest Affiliate - Peoria

Alabama

  • Children's Hospital of Alabama - Birmingham

Arizona

  • Kingman Regional Medical Center - Kingman

Delaware

  • Alfred I duPont Hospital for Children - Wilmington

District of Columbia

  • Children's National Medical Center - Washington D.C.

Hawaii

  • Kapiolani Medical Center for Women and Children - Honolulu

Trial Details

FieldValue
Enrollment Target 549 participants
Start Date 2022-04-08
Est. Completion 2027-09-30

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT05228275

The ClinicalTrials.gov registry entry for NCT05228275 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 549 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (52% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.

NCT05228275 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT05228275 about?

NCT05228275 is a clinical study titled "Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer". This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the body's immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer ...

What is the current status of trial NCT05228275?

This trial is currently active not recruiting. The enrollment target is 549 participants. The study started on 2022-04-08. Estimated completion is 2027-09-30.

What conditions does trial NCT05228275 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, COVID-19 Infection.

What interventions are being tested in trial NCT05228275?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER).

Who is sponsoring clinical trial NCT05228275?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05228275 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.